Effect of Bimekizumab on Patient-Reported Disease Impact in Patients with Psoriatic Arthritis: 1-Year Results from Two Phase 3 Studies.

Laure GossecAna-Maria OrbaiMaarten de WitLaura C CoatesAlexis OgdieBarbara InkJason CoarseJérémy LambertVanessa TaiebDafna D Gladman

Published in: Rheumatology (Oxford, England) (2024)

Bimekizumab treatment resulted in rapid and sustained clinically meaningful improvements in disease impact up to 1 year in bDMARD-naïve and TNFi-IR patients with PsA.

Keyphrases

patient reported
prostate cancer
radical prostatectomy
replacement therapy
smoking cessation